ACE INHIBITOR MARKET SWITCH TO GENERICS MAY BE HELD BACK BY MERCK-MEDCO TACTICS, LAW FIRM TELLS FTC; FDA MAINTAINS INTEREST IN PBM MARKETING TECHNIQUES
Executive Summary
The uptake of generics within the ACE inhibitor category when captopril comes off patent may be slowed by preferred product choices currently being made by Medco, the Washington, D.C. law firm of Fox, Bennett & Turner maintains in recent comments to the Federal Trade Commission.